MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

Overview of attention for article published in Stem Cell Research & Therapy, January 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 2,754)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 14 news stories from 14 outlets.

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem…

Intratracheal administration of NurOwn® derived exosomes significantly improves lung function and histology in a mouse model of…

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem…

Intratracheal administration of NurOwn® derived exosomes significantly improves lung function and histology in a mouse model of…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 10 additional news stories.